

Performance Against Time to Target

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
		NCRN561 : The regorafenib in patients with hepatocellular carcinoma								
13/LO/0150	119662	(RESORCE)	Number Agreed		2	2 Date Agreed	01/08/2015	1	07/10/2015	Recruitment Finished
12/NW/0641	108307	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	Number Agreed		9	9 Date Agreed	01/12/2015	16	27/08/2015	Recruitment Finished
13/WA/0101	123496	CCRN 2088 (Pneumonia)	Number Agreed		6	6 Date Agreed	30/04/2016	0	24/09/2015	Withdrawn By Sponsor
13/LO/0418	112763	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	Number Agreed		2	2 Date Agreed	31/10/2017	1	18/02/2016	Withdrawn By Host
		MCRN 2419: KOGNITO (Kuvan)?s effect on the cOGNITion of children								
13/LO/0945	130164	with phenylketOnuria)	Number Agreed		2	2 Date Agreed	30/09/2015	2	30/09/2015	Recruitment Finished
13/WS/0304	141071	EVARREST (The Fibrin Pad CV Phase III Study)	Number Agreed		10	10 Date Agreed	31/12/2015	8	30/07/2015	Withdrawn By Sponsor
14/LO/0036	134228	NCRN2555 - TOWER Study (00103311)	Number Agreed		5	5 Date Agreed	31/01/2016	3	04/09/2015	Withdrawn By Sponsor
		GWCA1208 - Study of Sativex in Patients with Recurrent								
13/YH/0126	126242	Glioblastoma	Number Agreed		4	4 Date Agreed	31/08/2015	3	04/08/2015	Recruitment Finished
13/EE/0367	138166	CCRN 2215 (Crohn's)	Number Agreed		3	3 Date Agreed	30/09/2015	0	30/09/2015	Recruitment Finished
13/LO/0716	112718	CCRN 2159 (Uveitis)	Number Agreed		4	4 Date Agreed	30/06/2016	0	21/09/2015	Withdrawn By Sponsor
13/LO/0717	124878	CL3-78989-006. EYEGUARD-C study	Number Agreed		4	4 Date Agreed	30/11/2015	6	21/09/2015	Recruitment Finished
14/EM/0034	141471	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	Number Agreed		2	2 Date Agreed	30/11/2015	1	04/09/2015	Withdrawn By Sponsor
13/LO/1608	135821	Study of efficacy and safety of nilotinib in paediatric CML patients	Number Agreed		1	1 Date Agreed	31/12/2015	1	06/07/2015	Recruitment Finished
		CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in								
14/SC/1014	156913	pancreatic adenocarcinoma	Number Agreed		2	2 Date Agreed	30/09/2015	4	08/01/2016	Recruitment Finished
		AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy								
14/EE/1063	156834	(AURA3)	Number Agreed		3	3 Date Agreed	02/09/2015	0	27/08/2015	Recruitment Finished
13/SC/0268	124775	CCRN2100 (Cystic fibrosis)	Number Agreed		3	3 Date Agreed	31/07/2015	1	06/08/2015	Recruitment Finished
14/YH/1124	160884	EXTEND (2819MA1002)	Number Agreed		3	3 Date Agreed	28/02/2016	0	04/02/2016	Recruitment Finished
13/WM/0143	116688	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	Number Agreed		1	1 Date Agreed	31/01/2016	2	01/09/2015	Recruitment Finished
14/NI/1075	161871	CHIL3670 (ALX0171-C104)	Number Agreed		1	1 Date Agreed	31/03/2016	0	10/09/2015	Withdrawn By Host
		GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE								
14/NE/1099	144103	TO TNF INHIBITORS	Number Agreed		1	1 Date Agreed	31/12/2017	0	08/09/2015	Withdrawn By Sponsor
14/SC/0181	148882	Elagolix in Endometriosis Associated Pain - Extension	Number Agreed		1	1 Date Agreed	31/12/2015	1	31/12/2015	Recruitment Finished
15/SC/0054	171682	CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma)	Number Agreed		6	6 Date Agreed	30/06/2016	4	07/09/2015	Withdrawn By Sponsor
		CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or								
14/LO/1490	158617	stage IV Melanoma (CA209-172)	Number Agreed		3	3 Date Agreed	30/10/2015	3	18/01/2016	Recruitment Finished
14/YH/1090	158372	QUIET-1	Number Agreed		4	4 Date Agreed	31/12/2015	0	08/10/2015	Withdrawn By Sponsor
		SMTC11004: Paediatric Subjects with Duchenne Muscular Dystrophy								
15/LO/0920	181642	(DMD)	Number Agreed		1	1 Date Agreed	19/02/2016	1	18/02/2016	Recruitment Finished
		M14-011: Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in								
15/LO/0273	149700	Subjects with Early Stage Triple Negative Breast Cancer (TNBC)	Number Agreed		8	8 Date Agreed	29/02/2016	1	18/03/2016	Recruitment Finished
		Protocol 083: MK5172A + Sofosbuvir +/-RBV in Cirrhotic GT3 Subjects								
15/SS/0186	190856	(MK-5172-083)	Number Agreed		6	6 Date Agreed	24/03/2016	4	24/03/2016	Recruitment Finished
		MK5172/ MK3682 with MK8742 or MK8408 in HCV GT1, GT2, and								
15/EE/0100	163708	GT4 Infected Subjects	Number Agreed		5	5 Date Agreed	01/02/2016	4	25/03/2016	Recruitment Finished
14/YH/1269	160993	CHIL3644 I.V. Tapentadol in post op pain	Number Agreed		1	1 Date Agreed	30/06/2016	0	04/04/2016	Withdrawn By Host
15/NW/0573	174966	CHIL4421 (NP25737)	Number Agreed		1	1 Date Agreed	30/01/2017	0	10/05/2016	Withdrawn By Sponsor
15/LO/0691	174324	Checkmate - 171	Number Agreed		4	4 Date Agreed	01/04/2016	4	01/06/2016	Recruitment Finished
14/SC/1311	155403	MCRN3165 (SD744) Cubist PSI Osteomyelitis	Number Agreed		3	3 Date Agreed	30/06/2016	0	09/06/2016	Recruitment Finished